Evidence map›Paper›PMID 40931195›Full record

ArticleMolecular systems biology2025

Epigenomic landscape of single vascular cells reflects developmental origin and disease risk loci.

Chad S Weldy, Soumya Kundu, João Monteiro, Wenduo Gu, Albert J Pedroza, Alex R Dalal, Matthew D Worssam, Daniel Li, Brian Palmisano, Quanyi Zhao and 8 more

Abstract read
In one paragraph

Article in Molecular systems biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Chad S WeldyDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA. weldyc@stanford.edu.ORCID http://orcid.org/0000-0003-4652-6422
Soumya KunduDepartment of Computer Science, Stanford University, Stanford, CA, USA.
João MonteiroDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6481-6875
Wenduo GuDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3859-3150
Albert J PedrozaStanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-5291-5980
Alex R DalalStanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-9993-3817
Matthew D WorssamDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-4391-5377
Daniel LiDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-1015-6298
Brian PalmisanoDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-2140-1060
Quanyi ZhaoDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.
Disha SharmaDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-9486-2709
Trieu NguyenDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.
Ramendra KunduDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.
Michael P FischbeinStanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Jesse EngreitzDepartment of Genetics, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5754-1719
Anshul B KundajeDepartment of Computer Science, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3084-2287
Paul P ChengDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3429-2702
Thomas QuertermousDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA. tomq1@stanford.edu.ORCID http://orcid.org/0000-0002-7645-9067

Funding

Stanford Center for Connecting DNA Variants to Function and PhenotypeUM1HG011972 · NHGRI · STANFORD UNIVERSITY · PI JESSE M ENGREITZ, THOMAS QUERTERMOUS · 2021 to 2026
$10.5M
Scientific Core: Perturb-seq library generation, sequencing, and data analysisP01HL180323 · NHLBI · STANFORD UNIVERSITY · PI RAJAT M GUPTA · 2025 to 2026
$7.1M
Causal variant association mechanisms in TCF21 binding coronary disease lociR01HL134817 · NHLBI · STANFORD UNIVERSITY · PI THOMAS QUERTERMOUS · 2017 to 2026
$6.2M
The SMAD3 signaling network in coronary artery disease riskR01HL139478 · NHLBI · STANFORD UNIVERSITY · PI THOMAS QUERTERMOUS · 2018 to 2026
$3.7M
PDGFD regulates a transcriptional network to modulate smooth muscle cell transition and coronary artery disease riskR01HL156846 · NHLBI · STANFORD UNIVERSITY · PI QUERTERMOUS, THOMAS · 2021 to 2024
$2.7M
Identifying tobacco-genetic interactions through study of the aryl hydrocarbon receptor pathway.R01HL151535 · NHLBI · STANFORD UNIVERSITY · PI QUERTERMOUS, THOMAS · 2021 to 2024
$2.7M
LncRNA Transcriptional Mechanisms of Coronary Artery Disease RiskR01HL145708 · NHLBI · STANFORD UNIVERSITY · PI QUERTERMOUS, THOMAS · 2019 to 2022
$1.6M
Adventitial Fibroblast Phenotypic Modulation in AtherosclerosisR01HL179083 · NHLBI · STANFORD UNIVERSITY · PI Paul Po Sheng cheng · 2025 to 2026
$1.4M
Smad3-mediated gene-environment interaction and risk of tobacco-induced aneurysmsR01HL181441 · NHLBI · STANFORD UNIVERSITY · PI Philip S Tsao, Paul Po Sheng cheng · 2025 to 2026
$1.4M
From Locus to Function: Role of ZEB2 in Human Risk of Coronary Artery DiseaseK08HL153798 · NHLBI · STANFORD UNIVERSITY · PI CHENG, PAUL PO SHENG · 2020 to 2024
$933k
ADAR mediated RNA editing is a causal mechanism in coronary artery diseaseK08HL167699 · NHLBI · STANFORD UNIVERSITY · PI Chad S Weldy · 2023 to 2026
$664k
Gene Regulatory Mechanisms of the Coronary Artery Disease Gene PRDM16 on Smooth Muscle Cell Phenotypic ModulationK08HL177251 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Brian T. Palmisano · 2025 to 2026
$311k
American Heart Association (AHA) 20CDA35310303American Heart Association (AHA) 23CDA1042900American Heart Association (AHA) 23POST1018991American Heart Association (AHA) 24CDA1272805American Heart Association (AHA) 24POST1187860American Heart Association (AHA) 24SCEFIA1248386Chan Zuckerberg Initiative (CZI) ZF2019-002437HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) K08HL177251HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL179083HHS | NIH | NHLBI | Division of Intramural Research (DIR) F32HL160067HHS | NIH | NHLBI | Division of Intramural Research (DIR) K08HL153798HHS | NIH | NHLBI | Division of Intramural Research (DIR) K08HL167699HHS | NIH | NHLBI | Division of Intramural Research (DIR) L30HL159413HHS | NIH | NHLBI | Division of Intramural Research (DIR) R01HL134817HHS | NIH | NHLBI | Division of Intramural Research (DIR) R01HL139478HHS | NIH | NHLBI | Division of Intramural Research (DIR) R01HL145708HHS | NIH | NHLBI | Division of Intramural Research (DIR) R01HL151535HHS | NIH | NHLBI | Division of Intramural Research (DIR) R01HL156846NHGRI NIH HHS UM1 HG011972NHLBI NIH HHS F32 HL160067NHLBI NIH HHS K08 HL153798NHLBI NIH HHS K08 HL167699NHLBI NIH HHS K08 HL177251NHLBI NIH HHS L30 HL159413NHLBI NIH HHS P01 HL180323NHLBI NIH HHS R01 HL134817NHLBI NIH HHS R01 HL139478NHLBI NIH HHS R01 HL145708NHLBI NIH HHS R01 HL151535NHLBI NIH HHS R01 HL156846NHLBI NIH HHS R01 HL179083NHLBI NIH HHS R01 HL181441
6 · The paper itself

Abstract

Vascular sites have distinct susceptibility to atherosclerosis and aneurysm, yet the epigenomic and transcriptomic underpinning of vascular site-specific disease risk is largely unknown. Here, we performed single-cell chromatin accessibility (scATACseq) and gene expression profiling (scRNAseq) of mouse vascular tissue from three vascular sites. Through interrogation of epigenomic enhancers and gene regulatory networks, we discovered key regulatory enhancers to not only be cell type, but vascular site-specific. We identified epigenetic markers of embryonic origin including developmental transcription factors such as Tbx20, Hand2, Gata4, and Hoxb family members and discovered transcription factor motif accessibility to be vascular site-specific for smooth muscle, fibroblasts, and endothelial cells. We further integrated genome-wide association data for aortic dimension, and using a deep learning model to predict variant effect on chromatin accessibility, ChromBPNet, we predicted variant effects across cell type and vascular site of origin, revealing genomic regions enriched for specific TF motif footprints-including MEF2A, SMAD3, and HAND2. This work supports a paradigm that cell type and vascular site-specific enhancers govern complex genetic drivers of disease risk.

Indexed as

Epigenesis, GeneticAnimalsChromatinEndothelial CellsEnhancer Elements, GeneticEpigenomicsGene Expression ProfilingGene Regulatory NetworksGenetic Predisposition to DiseaseGenome-Wide Association StudyMiceSingle-Cell AnalysisTranscription FactorsChromatinTranscription FactorsDevelopmentEpigenomicsGenomicsSingle-Cell TranscriptomicsVascular Biology

Identifiers

PMID40931195
PMCPMC12583710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.